MedTrace Logo

PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction

NCT07533747 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-04-16

No results posted yet for this study

Summary

Some people experience chest pain and shortness of breath, but when they have tests, no blockages are found in their main heart arteries. The most common cause of symptoms is related to abnormalities in the small blood vessels, also known as 'small vessel angina' or Coronary Microvascular Dysfunction (CMD). Currently, the diagnosis of CMD requires additional measurements of blood flow in the heart vessel during a minimally invasive procedure known as a coronary angiogram.

CMD affects many people and can lead to repeated hospital visits and a lower quality of life, and diagnosing the condition leads to better patient outcomes. However, there are still no widely available, proven treatments for this condition and therefore several patients remain symptomatic.

This study aims to find better ways to treat CMD, especially by understanding how the heart uses energy and how this might relate to symptoms.

Conditions

  • Coronary Microvascular Dysfunction (CMD)

Interventions

DRUG

Empagliflozin 10mg OD

Drug

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2031-05-31
Completion
2031-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07533747 on ClinicalTrials.gov